Compare NSSC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | EVO |
|---|---|---|
| Founded | 1969 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | NSSC | EVO |
|---|---|---|
| Price | $38.01 | $3.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $47.50 | $7.00 |
| AVG Volume (30 Days) | ★ 306.4K | 213.1K |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | $186,786,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $13.13 | N/A |
| Revenue Next Year | $9.55 | $8.52 |
| P/E Ratio | $31.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.00 | $2.84 |
| 52 Week High | $48.12 | $4.80 |
| Indicator | NSSC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 50.67 |
| Support Level | $39.20 | $3.58 |
| Resistance Level | $43.19 | $3.66 |
| Average True Range (ATR) | 1.29 | 0.08 |
| MACD | -0.44 | 0.02 |
| Stochastic Oscillator | 7.73 | 40.82 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.